Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) treatment relies on targeted therapies like tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase (ALK) inhibitors due to limitations of traditional platinum-based chemotherapy.
• Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) signaling pathways are crucial in cancer progression and represent significant therapeutic targets.

Purpose of the Study:

• To investigate the anticancer potential of Verrucarin J (VJ), a novel small molecule, against NSCLC cell lines.
• To elucidate the molecular mechanisms underlying VJ's anti-cancer effects, focusing on EGFR, AKT, and downstream signaling pathways.

Main Methods:

• Treatment of H460 and A549 NSCLC cell lines with Verrucarin J (VJ).
• Assessment of cell viability, proliferation, colony formation, and apoptosis.
• Analysis of signaling pathway modulation, including phosphorylated EGFR (pEGFR) and AKT (pAKT), and downstream targets mTOR and NF-κB.
• Evaluation of cell invasion, migration, and expression of mesenchymal markers (N-cadherin, Slug, β-catenin, vimentin).

Main Results:

• Verrucarin J significantly inhibited NSCLC cell growth, proliferation, and colony formation while inducing apoptosis.
• VJ treatment led to the downregulation of EGFR and AKT signaling pathways.
• VJ suppressed pro-survival signaling pathways including mTOR and NF-κB.
• Verrucarin J abrogated the invasive and migratory potential of NSCLC cells and reduced mesenchymal marker expression.

Conclusions:

• Verrucarin J demonstrates potent anticancer activity against NSCLC cell lines.
• VJ's mechanism involves the inhibition of EGFR and AKT signaling, leading to reduced cell growth and metastasis.
• Verrucarin J represents a promising therapeutic candidate for NSCLC, warranting further investigation.